Dublin, Dec. 19, 2016 -- Research and Markets has announced the addition of the "Opioid Addiction Drugs Price Analysis and Strategies - 2016" report to their offering.
Opioid Addiction Drugs Price Analysis and Strategies 2016, provides drug pricing data and benchmarks in the global Opioid Addiction market.
The research answers the following questions:
- What are the key drugs marketed for Opioid Addiction and their clinical attributes? How are they positioned in the Global Opioid Addiction market?
- What are the unit prices and annual treatment cost for Opioid Addiction therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
- What are the unmet needs in the global Opioid Addiction drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Opioid Addiction?
Research Scope:
- Treatment Options - Identify key drugs marketed and prescribed for Opioid Addiction including trade name, molecule name, and company
- Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Opioid Addiction
- Market Positioning - Identify how drugs are clinically and commercially positioned in the global Opioid Addiction market
- Opioid Addiction Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed
- Find out how the price advanced from 2012 and forecast to 2021
- Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape
- Opioid Addiction New Drug Pricing - Identify the effective pricing strategy for a new drug launch
Key Topics Covered:
1. Treatment Options
2. Drugs Clinical Attributes
3. Drugs Market Positioning
4. Drugs Price Analysis
5. Drugs Price Benchmarks
6. Drug Pricing & Reimbursement Landscape
7. Drugs Price Forecast
8. Market Unmet Needs
9. New Drug Pricing
For more information about this report visit http://www.researchandmarkets.com/research/cd6kww/opioid_addiction
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Addiction Disorders Drugs


SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Instagram Outage Disrupts Thousands of U.S. Users
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 



